vs
阿普塔集团（ATR）与CBIZ, Inc.（CBZ）财务数据对比。点击上方公司名可切换其他公司
阿普塔集团的季度营收约是CBIZ, Inc.的1.8倍（$962.7M vs $542.7M），阿普塔集团净利率更高（7.7% vs -14.6%，领先22.4%），CBIZ, Inc.同比增速更快（100.0% vs 13.5%），CBIZ, Inc.自由现金流更多（$175.5M vs $96.9M），过去两年CBIZ, Inc.的营收复合增速更高（13.7% vs 2.6%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
CBIZ, Inc.是美国知名的金融、保险及咨询服务提供商，总部位于俄亥俄州独立市，为美国规模最大的会计、保险经纪、金融与咨询服务机构之一。集团在全美设有120多个办事处，拥有近7000名员工，1996年起在纽交所上市，1997年起使用股票代码CBZ交易。
ATR vs CBZ — 直观对比
营收规模更大
ATR
是对方的1.8倍
$542.7M
营收增速更快
CBZ
高出86.5%
13.5%
净利率更高
ATR
高出22.4%
-14.6%
自由现金流更多
CBZ
多$78.7M
$96.9M
两年增速更快
CBZ
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $542.7M |
| 净利润 | $74.3M | $-79.4M |
| 毛利率 | — | — |
| 营业利润率 | 11.0% | 43.1% |
| 净利率 | 7.7% | -14.6% |
| 营收同比 | 13.5% | 100.0% |
| 净利润同比 | -26.4% | 4.2% |
| 每股收益（稀释后） | $1.13 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCBZ
| Q1 26 | — | $542.7M | ||
| Q4 25 | $962.7M | $542.7M | ||
| Q3 25 | $961.1M | $693.8M | ||
| Q2 25 | $966.0M | $683.5M | ||
| Q1 25 | $887.3M | $838.0M | ||
| Q4 24 | $848.1M | $460.3M | ||
| Q3 24 | $909.3M | $438.9M | ||
| Q2 24 | $910.1M | $420.0M |
净利润ATRCBZ
| Q1 26 | — | $-79.4M | ||
| Q4 25 | $74.3M | $-79.4M | ||
| Q3 25 | $127.9M | $30.1M | ||
| Q2 25 | $111.7M | $41.9M | ||
| Q1 25 | $78.8M | $122.8M | ||
| Q4 24 | $100.9M | $-90.7M | ||
| Q3 24 | $100.0M | $35.1M | ||
| Q2 24 | $90.5M | $19.8M |
毛利率ATRCBZ
| Q1 26 | — | — | ||
| Q4 25 | — | -9.4% | ||
| Q3 25 | — | 13.0% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.2% | ||
| Q4 24 | — | -13.4% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | — | 12.8% |
营业利润率ATRCBZ
| Q1 26 | — | 43.1% | ||
| Q4 25 | 11.0% | -15.7% | ||
| Q3 25 | 14.2% | 8.5% | ||
| Q2 25 | 14.9% | 8.8% | ||
| Q1 25 | 12.8% | 23.9% | ||
| Q4 24 | 14.2% | -23.2% | ||
| Q3 24 | 15.2% | 11.3% | ||
| Q2 24 | 13.8% | 7.5% |
净利率ATRCBZ
| Q1 26 | — | -14.6% | ||
| Q4 25 | 7.7% | -14.6% | ||
| Q3 25 | 13.3% | 4.3% | ||
| Q2 25 | 11.6% | 6.1% | ||
| Q1 25 | 8.9% | 14.7% | ||
| Q4 24 | 11.9% | -19.7% | ||
| Q3 24 | 11.0% | 8.0% | ||
| Q2 24 | 9.9% | 4.7% |
每股收益（稀释后）ATRCBZ
| Q1 26 | — | $-1.28 | ||
| Q4 25 | $1.13 | $-1.22 | ||
| Q3 25 | $1.92 | $0.48 | ||
| Q2 25 | $1.67 | $0.66 | ||
| Q1 25 | $1.17 | $1.91 | ||
| Q4 24 | $1.48 | $-1.84 | ||
| Q3 24 | $1.48 | $0.70 | ||
| Q2 24 | $1.34 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $18.3M |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $2.7B | $1.8B |
| 总资产 | $5.3B | $4.4B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCBZ
| Q1 26 | — | $18.3M | ||
| Q4 25 | $409.5M | $18.3M | ||
| Q3 25 | $264.8M | $17.0M | ||
| Q2 25 | $169.8M | $39.8M | ||
| Q1 25 | $136.8M | $8.8M | ||
| Q4 24 | $226.2M | $13.8M | ||
| Q3 24 | $327.9M | $1.1M | ||
| Q2 24 | $223.9M | $1.1M |
总债务ATRCBZ
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — |
股东权益ATRCBZ
| Q1 26 | — | $1.8B | ||
| Q4 25 | $2.7B | $1.8B | ||
| Q3 25 | $2.8B | $1.9B | ||
| Q2 25 | $2.7B | $1.9B | ||
| Q1 25 | $2.5B | $1.9B | ||
| Q4 24 | $2.5B | $1.8B | ||
| Q3 24 | $2.5B | $927.9M | ||
| Q2 24 | $2.4B | $891.4M |
总资产ATRCBZ
| Q1 26 | — | $4.4B | ||
| Q4 25 | $5.3B | $4.4B | ||
| Q3 25 | $5.1B | $4.5B | ||
| Q2 25 | $4.9B | $4.5B | ||
| Q1 25 | $4.5B | $4.6B | ||
| Q4 24 | $4.4B | $4.5B | ||
| Q3 24 | $4.6B | $2.1B | ||
| Q2 24 | $4.5B | $2.2B |
负债/权益比ATRCBZ
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $192.5M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $175.5M |
| 自由现金流率自由现金流/营收 | 10.1% | 32.3% |
| 资本支出强度资本支出/营收 | 9.0% | — |
| 现金转化率经营现金流/净利润 | 2.47× | — |
| 过去12个月自由现金流最近4个季度 | $299.6M | $444.5M |
8季度趋势，按日历期对齐
经营现金流ATRCBZ
| Q1 26 | — | $192.5M | ||
| Q4 25 | $183.7M | $143.6M | ||
| Q3 25 | $177.6M | $24.0M | ||
| Q2 25 | $126.0M | $113.1M | ||
| Q1 25 | $82.7M | $-88.3M | ||
| Q4 24 | $178.2M | $55.5M | ||
| Q3 24 | $229.3M | $43.7M | ||
| Q2 24 | $143.6M | $88.2M |
自由现金流ATRCBZ
| Q1 26 | — | $175.5M | ||
| Q4 25 | $96.9M | $141.7M | ||
| Q3 25 | $114.3M | $22.1M | ||
| Q2 25 | $62.5M | $105.2M | ||
| Q1 25 | $25.9M | $-93.4M | ||
| Q4 24 | $112.2M | $52.3M | ||
| Q3 24 | $162.7M | $41.1M | ||
| Q2 24 | $75.4M | $86.3M |
自由现金流率ATRCBZ
| Q1 26 | — | 32.3% | ||
| Q4 25 | 10.1% | 26.1% | ||
| Q3 25 | 11.9% | 3.2% | ||
| Q2 25 | 6.5% | 15.4% | ||
| Q1 25 | 2.9% | -11.2% | ||
| Q4 24 | 13.2% | 11.4% | ||
| Q3 24 | 17.9% | 9.4% | ||
| Q2 24 | 8.3% | 20.5% |
资本支出强度ATRCBZ
| Q1 26 | — | — | ||
| Q4 25 | 9.0% | 0.4% | ||
| Q3 25 | 6.6% | 0.3% | ||
| Q2 25 | 6.6% | 1.2% | ||
| Q1 25 | 6.4% | 0.6% | ||
| Q4 24 | 7.8% | 0.7% | ||
| Q3 24 | 7.3% | 0.6% | ||
| Q2 24 | 7.5% | 0.4% |
现金转化率ATRCBZ
| Q1 26 | — | — | ||
| Q4 25 | 2.47× | — | ||
| Q3 25 | 1.39× | 0.79× | ||
| Q2 25 | 1.13× | 2.70× | ||
| Q1 25 | 1.05× | -0.72× | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.29× | 1.25× | ||
| Q2 24 | 1.59× | 4.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
CBZ
暂无分部数据
